Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Operating Expenses: 2015-2025

Historic Operating Expenses for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $22.8 million.

  • Seres Therapeutics' Operating Expenses fell 21.74% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.8 million, marking a year-over-year decrease of 19.86%. This contributed to the annual value of $121.3 million for FY2024, which is 37.82% down from last year.
  • As of Q3 2025, Seres Therapeutics' Operating Expenses stood at $22.8 million, which was down 8.25% from $24.9 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Operating Expenses peaked at $76.9 million during Q2 2023, and registered a low of -$4.4 million during Q4 2022.
  • Its 3-year average for Operating Expenses is $38.6 million, with a median of $29.2 million in 2024.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 107.81% in 2022, then spiked by 937.27% in 2023.
  • Seres Therapeutics' Operating Expenses (Quarterly) stood at $56.7 million in 2021, then tumbled by 107.81% to -$4.4 million in 2022, then spiked by 937.27% to $37.0 million in 2023, then fell by 22.12% to $28.8 million in 2024, then fell by 21.74% to $22.8 million in 2025.
  • Its last three reported values are $22.8 million in Q3 2025, $24.9 million for Q2 2025, and $27.2 million during Q1 2025.